Develops drugs for blood cancers like leukemia and lymphoma.
Jun 2026Revenue $4.31M/yrExpenses $13.1M/yr
No trendCash runway ≈ 2 months from Jun 2026
Figures by year
When will Curis be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $4.31M and expenses $13.1M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $9.44M | $15.2M | −$5.71M |
| Dec 2024 | $10.9M | $55.5M | −$44.5M |
| Dec 2023 | $10.0M | $58.4M | −$48.3M |
| Dec 2022 | $10.2M | $63.2M | −$53.0M |
| Dec 2021 | $10.6M | $52.7M | −$42.1M |
| Dec 2020 | $10.8M | $35.7M | −$24.9M |
| Dec 2019 | $10.0M | $34.4M | −$24.4M |
| Dec 2018 | $10.4M | $39.8M | −$29.3M |
| Dec 2017 | $9.90M | $59.7M | −$49.8M |
| Dec 2016 | $7.53M | $65.6M | −$58.0M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.